Nuvation Bio Inc. announced that the first patient has been dosed in a Phase 1/2 study of NUV-1511, the Company's first DDC to enter the clinic. The dose escalation portion of the study employs a flexible design that allows for the potential to explore two dosing schedules for NUV-1511 with the goal of establishing the recommended Phase 2 dose. The study will initially evaluate safety and tolerability, pharmacokinetic profile, and assess for signs of clinical activity in patients with advanced solid tumors who previously received and progressed on or after treatment with Enhertu and/or Trodelvy per approved U.S. Food and Drug Administration (FDA) labeling, human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer, metastatic castration-resistant prostate cancer (mCRPC), advanced pancreatic cancer, and platinum-resistant ovarian cancer (PROC).
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.905 USD | +8.40% | +7.93% | +91.56% |
Apr. 17 | RBC Raises Price Target on Nuvation Bio to $5 From $4, Keeps Outperform, Speculative Risk | MT |
Apr. 10 | Nuvation Bio Closes Acquisition of AnHeart Therapeutics | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+91.56% | 704M | |
+2.58% | 42.75B | |
+47.70% | 41.61B | |
+12.19% | 41.34B | |
-8.83% | 26.59B | |
+7.96% | 25.49B | |
-22.80% | 18.12B | |
+31.17% | 12.24B | |
-1.48% | 11.76B | |
+8.45% | 11B |
- Stock Market
- Equities
- NUVB Stock
- News Nuvation Bio Inc.
- Nuvation Bio Inc. Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors